Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Long-Term Investments (2016 - 2023)

Tvardi Therapeutics' Long-Term Investments history spans 10 years, with the latest figure at $4.7 million for Q3 2023.

  • On a quarterly basis, Long-Term Investments fell 80.15% to $4.7 million in Q3 2023 year-over-year; TTM through Sep 2023 was $4.7 million, a 80.15% decrease, with the full-year FY2022 number at $11.4 million, down 83.73% from a year prior.
  • Long-Term Investments hit $4.7 million in Q3 2023 for Tvardi Therapeutics, down from $7.1 million in the prior quarter.
  • Over the last five years, Long-Term Investments for TVRD hit a ceiling of $70.6 million in Q4 2020 and a floor of $4.7 million in Q3 2023.
  • Historically, Long-Term Investments has averaged $38.1 million across 5 years, with a median of $47.2 million in 2022.
  • Biggest five-year swings in Long-Term Investments: skyrocketed 368.5% in 2021 and later crashed 86.74% in 2023.
  • Tracing TVRD's Long-Term Investments over 5 years: stood at $63.2 million in 2019, then increased by 11.73% to $70.6 million in 2020, then dropped by 1.15% to $69.8 million in 2021, then tumbled by 83.73% to $11.4 million in 2022, then crashed by 58.18% to $4.7 million in 2023.
  • Business Quant data shows Long-Term Investments for TVRD at $4.7 million in Q3 2023, $7.1 million in Q2 2023, and $9.1 million in Q1 2023.